AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21771709 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy with irinotecan, oxaliplatin, and cetuximab
Number of subjects: 48
Study 19254623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 15
Study 19254623 — intervention group
Group type: COMPARATOR
Intervention: Health education classes (control)
Number of subjects: 15
Study 17086891 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release clarithromycin 1000mg once daily (AECMR)
Number of subjects: 161
Study 17086891 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release clarithromycin 500mg twice daily (AECIR)
Number of subjects: 161
Study 16343235 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (Epirubicin 60 mg/m² iv + Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Number of subjects: 1282
Study 16343235 — intervention group
Group type: COMPARATOR
Intervention: TC (Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Number of subjects: 1282
Study 12525741 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' disease patients
Number of subjects: 16
Study 12525741 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 16
Study 10949157 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of functioning
Number of subjects: 1
Study 10949157 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 1
Study 10949157 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological symptomatology evaluation
Number of subjects: 1
Study 7745788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 300,000 units.day‐1 during intraoperative and postoperative three days
Number of subjects: 10
Study 7745788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 10
Study 2149704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 200 mg/day for 6 months
Number of subjects: 114
Study 2149704 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 114
Study 7013301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate and neuroleptics
Number of subjects: 90
Study 7013301 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 90
Study 31251407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 68
Study 31251407 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual care)
Number of subjects: 68
Study 29086063 — intervention group
Group type: COMPARATOR
Intervention: Glasdegib 100 mg diHCl formulation (fasted)
Number of subjects: 34
Study 29086063 — intervention group
Group type: COMPARATOR
Intervention: Glasdegib 100 mg small-particle size maleate formulation (fasted)
Number of subjects: 34
Study 29086063 — intervention group
Group type: COMPARATOR
Intervention: Glasdegib 100 mg large-particle size maleate formulation (fed)
Number of subjects: 34
Study 29086063 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg large-particle maleate formulation (fasted) with rabeprazole
Number of subjects: 34
Study 29086063 — intervention group
Group type: COMPARATOR
Intervention: Glasdegib 50 mg oral solution (fasted)
Number of subjects: 34
Study 25403438 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst transfer (day 5)
Number of subjects: 104
Study 25403438 — intervention group
Group type: COMPARATOR
Intervention: Cleavage stage transfer (day 3)
Number of subjects: 104
Study 25403438 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst transfer (day 5) in women 35 or older
Number of subjects: 104
Study 25403438 — intervention group
Group type: COMPARATOR
Intervention: Cleavage stage transfer (day 3) in women 35 or older
Number of subjects: 104
Study 24152746 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prediction models for α‐carotene
Number of subjects: 4180
Study 24152746 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prediction models for β‐carotene
Number of subjects: 4180
Study 24152746 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prediction models for β‐cryptoxanthin
Number of subjects: 4180
Study 24152746 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prediction models for lutein/zeaxanthin
Number of subjects: 4180
Study 24152746 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prediction models for lycopene
Number of subjects: 4180
Study 24152746 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prediction models for total carotenoids
Number of subjects: 4180
Study 21569437 — intervention group
Group type: EXPERIMENTAL
Intervention: VC measured by ventilometer in preoperative patients
Number of subjects: 52
Study 21569437 — intervention group
Group type: EXPERIMENTAL
Intervention: VC measured by inspirometer in preoperative patients
Number of subjects: 52
Study 21569437 — intervention group
Group type: EXPERIMENTAL
Intervention: VC measured by ventilometer in postoperative patients
Number of subjects: 52
Study 21569437 — intervention group
Group type: EXPERIMENTAL
Intervention: VC measured by inspirometer in postoperative patients
Number of subjects: 52
Study 18155872 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-basilic arteriovenous fistula (BBAVF)
Number of subjects: 105
Study 18155872 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic brachial-antecubital forearm loop (PTFE loop)
Number of subjects: 105
Study 16562408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-designated driver messages
Number of subjects: 1412
Study 16562408 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary rewards for driver sobriety
Number of subjects: 1412
Study 16562408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracelet with 'designated driver'
Number of subjects: 1412
Study 16562408 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1412
Study 12952499 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI 007 260 mg/m(2) administered as a 30-minute infusion without steroid pretreatment
Number of subjects: 460
Study 12952499 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m(2) administered over 3 hours with steroid pretreatment
Number of subjects: 460
Study 11023500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autografting
Number of subjects: 32
Study 9160642 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up study
Number of subjects: 49
Study 1423182 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCSF administered subcutaneously (SC) at 5 micrograms/kg twice daily for 14 days starting the day after chemotherapy
Number of subjects: 57
Study 1423182 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCSF administered SC at 10 micrograms/kg daily for 20 days starting 2 days after chemotherapy
Number of subjects: 57
Study 1423182 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCSF administered SC every 12 hours for 14 days
Number of subjects: 57
Study 1423182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prechemotherapy priming with GMCSF twice daily for 4 days (days -6 to -3)
Number of subjects: 57
Study 1423182 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCSF administered SC at 5 micrograms/kg twice daily
Number of subjects: 57
Study 1423182 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose GMCSF with antihistamines and ibuprofen
Number of subjects: 57
Study 6374679 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g nabumetone twice daily
Number of subjects: 18
Study 6374679 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 18
Study 30386143 — intervention group
Group type: EXPERIMENTAL
Intervention: LVLC-CTU (80 kVp and 240 mgI/mL) with IR
Number of subjects: 299
Study 30386143 — intervention group
Group type: COMPARATOR
Intervention: Conventional CTU (120 kVp and 350 mgI/mL) with filtered-back projection
Number of subjects: 299
Study 27154481 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) via a multifaceted strategy (decision aid, support of IVF nurse, reimbursement for an extra treatment cycle)
Number of subjects: 222
Study 27154481 — intervention group
Group type: COMPARATOR
Intervention: Standard IVF care (Control group)
Number of subjects: 222
Study 27154481 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM)
Number of subjects: 222
Study 25028951 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath stacking technique
Number of subjects: 30
Study 25028951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Number of subjects: 30
Study 22629840 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr-chloride fractional injection (50 Mbk)
Number of subjects: 50
Study 22629840 — intervention group
Group type: COMPARATOR
Intervention: Standard 150 Mbk injection (Control)
Number of subjects: 50
Study 20558431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1101
Study 20558431 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1101
Study 20558431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren and Valsartan
Number of subjects: 1101
Study 20558431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1101
Study 20558431 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy (Aliskiren, Valsartan, Combination)
Number of subjects: 1101
Study 18377854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia intervention 20 minutes before and throughout the surgical procedure
Number of subjects: 350
Study 18377854 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 350
Study 18377854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia intervention
Number of subjects: 350
Study 16160691 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA + EBT (14 Gy applied by an 192Ir source)
Number of subjects: 60
Study 16160691 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 60
Study 16160691 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA + EBT
Number of subjects: 60
Study 12823307 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine for confirmed dermatophyte onychomycosis for 12 weeks
Number of subjects: 35
Study 11880064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (PPS) therapy at doses of 300, 600, or 900 mg/day for 32 weeks
Number of subjects: 377
Study 11880064 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 377
Study 10025931 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ 400 mg/day
Number of subjects: 212
Study 10025931 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ 800 mg/day
Number of subjects: 212
Study 10025931 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ 1200 mg/day
Number of subjects: 212
Study 10025931 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1,000 mg/day)
Number of subjects: 212
Study 7546934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose botulinum toxin type A (240 units/session)
Number of subjects: 51
Study 7546934 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose botulinum toxin type A (120 units/session)
Number of subjects: 51
Study 7546934 — intervention group
Group type: COMPARATOR
Intervention: Low-dose botulinum toxin type A (60 units/session)
Number of subjects: 51
Study 2100355 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min aerobic exercise condition
Number of subjects: 57
Study 2100355 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control condition
Number of subjects: 57
Study 2100355 — intervention group
Group type: EXPERIMENTAL
Intervention: Digits backward problems during exercise
Number of subjects: 57
Study 2100355 — intervention group
Group type: COMPARATOR
Intervention: Digits backward problems in no-exercise group
Number of subjects: 57
Study 6452842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium nasal spray (80 micrograms, 4 times daily for 1 week)
Number of subjects: 40
Study 6452842 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 31705602 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollients in Prinsepia utilis Royle
Number of subjects: 309
Study 31705602 — intervention group
Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 309
Study 31292987 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CMX
Number of subjects: 24
Study 31292987 — intervention group
Group type: COMPARATOR
Intervention: CAF alone (control)
Number of subjects: 24
Study 27859599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 60
Study 27859599 — intervention group
Group type: COMPARATOR
Intervention: Control (avoided peanuts)
Number of subjects: 60
Study 25671762 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo 72 hours after surgical procedure
Number of subjects: 53
Study 25671762 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no shampooing)
Number of subjects: 53
Study 24072451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone (400 mg twice daily)
Number of subjects: 1405
Study 24072451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1405
Study 22936099 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable small perturbations
Number of subjects: 0
Study 22936099 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable large perturbations
Number of subjects: 0
Study 22936099 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable perturbations
Number of subjects: 0
Study 22936099 — intervention group
Group type: COMPARATOR
Intervention: Control participants (predictable perturbations)
Number of subjects: 0
Study 22936099 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with PD (predictable perturbations)
Number of subjects: 0
Study 22936099 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictably small-magnitude perturbations
Number of subjects: 0
Study 22936099 — intervention group
Group type: COMPARATOR
Intervention: Control participants (unpredictable perturbations)
Number of subjects: 0
Study 22936099 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with PD (unpredictable perturbations)
Number of subjects: 0
Study 18594127 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior/Posterior (A/P) training
Number of subjects: 48
Study 18594127 — intervention group
Group type: EXPERIMENTAL
Intervention: Medio/Lateral (M/L) training
Number of subjects: 48
Study 18594127 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 17332789 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dieting lifestyle intervention group (n = 17)
Number of subjects: 31
Study 17332789 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n = 14)
Number of subjects: 31
Study 15220949 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFA) - 33 g daily intake from partially hydrogenated soy oil containing 20 g of TFA
Number of subjects: 87
Study 15220949 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) - 33 g daily intake from fish oil with approximately 4 g of n-3 PUFA
Number of subjects: 87
Study 15220949 — intervention group
Group type: COMPARATOR
Intervention: Control fat - 33 g daily intake of control fat
Number of subjects: 87
Study 11205182 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hyperventilation for 20 minutes
Number of subjects: 8
Study 9924276 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + 50 g sugarbeet fibre/d
Number of subjects: 9
Study 9924276 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + 50 g commercial inulin/d
Number of subjects: 9
Study 9924276 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 7995207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin
Number of subjects: 0
Study 7995207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal lipid
Number of subjects: 0
Study 3055689 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy + flutamide
Number of subjects: 55
Study 3055689 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy + estramustine
Number of subjects: 55
Study 29747834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg folic acid + 10 mg enalapril
Number of subjects: 10789
Study 29747834 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 10789
Study 27622219 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (1000 mg capsules for 6 months)
Number of subjects: 50
Study 27622219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24669829 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9164 (1000 μg)
Number of subjects: 49
Study 24669829 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9164 (400 μg)
Number of subjects: 49
Study 24669829 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9164 (2800 μg)
Number of subjects: 49
Study 24669829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 22104540 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training: 3 × 3 min of bilateral dynamic squat exercises on a side-alternating vibration platform at 24-26 Hz three times per week
Number of subjects: 82
Study 22104540 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON): Same amount of exercise time without WBV
Number of subjects: 82
Study 22104540 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training
Number of subjects: 82
Study 22104540 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 82
Study 20573635 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (2 doses: 2 h before surgery and on first postoperative day)
Number of subjects: 50
Study 20573635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19039292 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention program
Number of subjects: 591
Study 19039292 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 591
Study 16020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 120
Study 16020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated diet rich in alpha-linolenic acid
Number of subjects: 120
Study 16020749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16020749 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 120
Study 15063960 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning seminar on breastfeeding (2 hours)
Number of subjects: 73
Study 15063960 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care (Control)
Number of subjects: 73
Study 10868864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg) plus Metformin (500 mg)
Number of subjects: 12
Study 10868864 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg)
Number of subjects: 12
Study 10868864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9268758 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 300 mg/day (Group 1)
Number of subjects: 12
Study 9268758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery (Group 2)
Number of subjects: 12
Study 9268758 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 300 mg/day followed by cryosurgery (Group 3)
Number of subjects: 12
Study 9268758 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (Groups 1 and 3)
Number of subjects: 12
Study 8096958 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM plus ABMT
Number of subjects: 40
Study 8096958 — intervention group
Group type: COMPARATOR
Intervention: mini-BEAM
Number of subjects: 40
Study 3955536 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week for 16 weeks)
Number of subjects: 0
Study 3955536 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week for 16 weeks) plus vitamin A (100,000 IU/week for 16 weeks)
Number of subjects: 0
Study 3955536 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 3046484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin hydrochloride (250 mg four times a day) in study A
Number of subjects: 343
Study 3046484 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin monohydrate (500 mg two times a day) in study A
Number of subjects: 343
Study 3046484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin hydrochloride (500 mg two times a day) in study B
Number of subjects: 343
Study 3046484 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin monohydrate (250 mg four times a day) in study B
Number of subjects: 343
Study 3046484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (cephalexin hydrochloride and cephalexin monohydrate)
Number of subjects: 343
Study 30611273 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation-enriched VP group (N=35)
Number of subjects: 103
Study 30611273 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (N=37)
Number of subjects: 103
Study 30611273 — intervention group
Group type: COMPARATOR
Intervention: Static VP group (N=31)
Number of subjects: 103
Study 30611273 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 103
Study 29256191 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove groups (cold gloves layered under mittens, mittens, cold gloves)
Number of subjects: 180
Study 29256191 — intervention group
Group type: COMPARATOR
Intervention: Bare hands
Number of subjects: 180
Study 29256191 — intervention group
Group type: EXPERIMENTAL
Intervention: Other glove groups (examination gloves, flight gloves, leather gloves, glove liners, glove liners layered under leather gloves)
Number of subjects: 180
Study 25951227 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal right/cathodal left tDCS stimulation
Number of subjects: 0
Study 25951227 — intervention group
Group type: COMPARATOR
Intervention: Anodal left/cathodal right tDCS stimulation
Number of subjects: 0
Study 25951227 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 0